The Korean Journal of Nuclear Medicine (대한핵의학회지)

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

The Role of PET in Thyroid Cancer

갑상선암에서 PET의 역할

  • Yeo, Jeong-Seok (Department of Nuclear Medicine, Asan Medical Center University of Ulsan College of Medicine)
  • 여정석 (울산대학교 의과대학 핵의학과)
  • Published : 2002.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

The role of PET in the diagnosis and management of thyroid cancer is discussed. The major role of F-18 FDG PET is on patients with discordant negative I-131 scan and a positive serum thyroglobulin values. F-18 FDG PET scan localized metastatic sites in I-131 scan-negative thyroid carcinoma patients with high accuracy. F-18 PET is also valuable in medullary thyroid cancer with high calcitonin level. Focal thyroid uptake in patients with non-thyroidal diseas has high likelihood of thyroid cancer.

Keywords

References

  1. Park CK, Woo KS, Kim CM, Lee YW, KooKH. A Clinical and pathological study onneoplasms of the thyroid among Koreans.Korean J Pathol 1982;16:207-16.
  2. Kim YK, Chung J-K, Lee DS, Jeong JM, ChoBY, MC Lee, et al. Ablation of remnant thyroidtissue with 1-131 in well differentiated thyroidcancer after surgery. Korean J Nucl Med1997;31:339-45.
  3. McDougall IR, Davidson J, Segall GM. Positronemission tomography of the thyroid, with anemphasis on thyroid cancer. Nucl Med Commun2001;22(5):485-92.
  4. Fiene U. Fluoro-18-deoxyg1ucose positronemission tomography in differentiated thyroidcarcinoma. Eur J Endocrinol 1998;138:492-6.
  5. Dietlin M, Scheidhauer K, Voth E, Theissen P,Schicha H. Fluorine-18 fluorodeoxyglucosepositron emission tomography and iodine- 131whole-body scintigraphy in the follow- up ofdifferentiated thyroid cancer. Eur J Nucl Med1997;24:1342-8.
  6. Adler LP, Bloom AD. Positron emissiontomography of thyroid masses. Thyroid 1993;3:195-200.
  7. Uematsu H, Sadato N, Ohtsubo T, Tsuchida T,Nakamura S, Sugimoto K, et al. Fluorine-18fluorodeoxyglucosePET versus thallium-201scintigraphy evaluation of thyroid tumors. J NuclMed 1998;39:453-9.
  8. Davis PW, Perrier ND, Adler L, Levine EA.Incidental thyroid carcinoma identified bypositron emission tomography scanning obtainedfor metastatic evaluation. Am Surg 2001;67(6):582-4.
  9. Cohen MS, Arslan N, Dehdashti F, DohertyGM, Lairmore TC, Brunt LM, et al. Risk ofmalignancy in thyroid incidentalornas identified by fluorodeoxyglucose-positron emission tomography. Surgery 2001;130(6):941-6.
  10. Van den Bruel A, Maes A, De Potter T,Mortelmans L, Drijkoningen M, VanDamme B,et al. Clinical relevance of thyroid fluorodeoxyglucose-whole body positron emission tomographyincidentaloma. J Clin Endocrinol Metab 2002;87(4):1517-20.
  11. Gabriel M, Erler H, Donnemiller E, RiccabonaG. Increased F-18 fluorodeoxyglucose accumulationin a benign neurofibroma--a pitfall in apatient with thyroid cancer: a case report.Nuklearmedizin 2002;41(2):N14-5.
  12. Schlumberger M, Mancusi F, Baudin E, PaciniF. 131-1 therapy for elevated thyroglobulinlevels. Thyroid 1997;7:273-6.
  13. Frilling A, Tecklenborg K, Gorges R, Weber F,Clausen M, Broelsch EC. Preoperative diagnosticvalue of C8F] fluorodeoxyglucose positron emissiontomography in patients with radioiodine-negativerecurrent well-differentiated thyroid carcinoma.Ann Surg 2001;234(6):804-1l.
  14. Hooft L, Hoekstra OS, Deville W, Lips P, TeuleGJ, Boers M, et al. Diagnostic accuracy of18F-fluorodeoxyglucose positron emission tomographyin the follow-up of papillary or follicularthyroid cancer. J Clin Endocrinol Metab2001;86(8):3779-86.
  15. Lotty H, Otto S, Walter D, Paul L, Gerrit J,Maarten B, et al. Diagnostic Accuracy of18F-Fluorodeoxyglucose Positron Emission Tomographyin the Follow-Up of Papillary orFollicular Thyroid Cancer The Journal ofClinical Endocrinology & Metabolism 86(8):3779-86.
  16. Chung JK, So Y, Lee JS, Choi CW, Lim SM,Lee DS, et al. Value of FDG PET in papillarythyroid carcinoma with negative 1311 whole-bodyscan. J Nucl Med 1999; 40:486-92.
  17. Yeo JS, Chung JK, So Y, Kim S, Lee E, LeeDS, et al. F-18-fluorodeoxyglucose positronemission tomography as a presurgical evaluationmodality for 1-131 scan-negative thyroid carcinomapatients with local recurrence in cervicallymph nodes. Head Neck 2001;23(2):94-103.
  18. Helal BO, Merlet P, Toubert ME, Franc B,Schvartz C, Gauthier-Koelesnikov H, et al.Clinical impact of 18F_FDG PET in thyroidcarcinoma patients with elevated thyroglobulinlevels and negative 1311 scanning results aftertherapy. J Nucl Med 2001; 42(10):1464-9.
  19. Boerner AR, Petrich T, Weckesser E, Fricke H,Hofmann M, Otto D, et al. Monitoring isotretinointherapy in thyroid cancer using 18F_FDGPET. Eur J Nucl Med Mol Imaging 2002;29(2):231-6.
  20. DieW M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 2001;28(11):1671-6.
  21. Musholt TJ, Musholt PB, Dehdashti F, MoleyJF. Evaluation of fluorodeoxyglucose- positronemission tomographic scanning and its associationwith glucose transporter expression in medullarythyroid cancer and pheochromocytoma: a clinicaland molecular study. Surgery 1997;122:1049-60.
  22. Szakall S Jr, Esik 0, Bajzik G, Repa I, DabasiG, Sinkovics I, et al. 18F_FDG PET detection oflymph node metastases in medullary thyroidcarcinoma. J Nucl Med 2002 Jan;43(1):66-7l.
  23. Plotkin M, Hautzel H, Krause BJ, Schmidt D,Larisch R, Mottaghy FM, et al. Implication of2-18fluor-2-deoxyglucose positron emissiontomography in the follow-up of Hurthle cellthyroid cancer. Thyroid 2002; 12(2):155-61.
  24. Conti PS, Durski JM, Bacqai F, Grafto ST,Singer PA. Imaging of locally recurrent andmetastatic thyroid cancer with positron emissiontomography. Thyroid 1999;9:797- 804.
  25. Zhu Z, Chou C, Yen TC, Cui R Elevated F-18FDG uptake in laryngeal muscles mimickingthyroid cancer metastases. Clin Nucl Med2001;26(8):689-91.
  26. 1. Igerc, G. Kumnig, M. Heinisch, E. Kresnik, P.Mikosch, H.J. Gallowitsch, et al. Vocal CordMuscle Activity as a Drawback to FDG-PET inthe Followup of Differentiated Thyroid Cancer.Thyroid 2002;12(1): 87-9.
  27. McDougall IR, Davidson J, Segall GM. Positronemission tomography of the thyroid, with anemphasis on thyroid cancer. Nucl Med Commun2001;22(5):485-92.
  28. Park CH, Lee EJ, Kim JK, Joo HJ, Jang JS.Focal F-18 FDG uptake in a nontoxicautonomous thyroid nodule. Clin Nucl Med2002;27(2):136-7.
  29. Sisson rc, Ackerman RJ, Meyer MA, Wahl RL.Uptake of 18-fluoro-2-deoxy-D- glucose bythyroid cancer: implications for diagnosis andtherapy. J Clin Endocrinol Metabol 1993;77:1090-4.
  30. Wang W, Macapinlac H, Larson SM, Yeh SD,Akhurst T, Finn RD, et al. C8F]-2-fluoro-2deoxy-D-g1ucose positron emission tomographylocalizes residual thyroid cancer in patients withnegative diagnostic 1311 whole body scans andelevated serum thyroglobulin levels. J ClinEndocrinol Metab 1999;84(7):2291-302.
  31. Moog F, Linke R, Manthey N, Tiling R,Knesewitsch P, Tatsch K et al. Influence ofthyroid-stimulating hormone levels on uptake ofFDG in recurrent and metastatic differentiatedthyroid carcinoma. J Nucl Med 2000;41(12):1989-95.
  32. Petrich T, Borner AR, Otto D, Hofmann M,Knapp WHo Influence of rhTSH on C8F]fluorodeoxyg1ucoseuptake by differentiated thyroidcarcinoma. Eur J Nucl Med 2002;29(5):641-7.